Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), announced today that it has been awarded a Therapeutic Pipeline Programme grant of approximately 0.5M USD from The Michael J Fox Foundation for Parkinson’s Research (MJFF).
MISSION Therapeutics is a specialist pharmaceutical company whose aim is to translate new molecular understandings of human cell biology into drugs that will markedly improve the management of life-threatening diseases, particularly cancer.
Telephone: +44 (0)1223 607 340
The Glenn Berge Building Building 940 Babraham Research Campus, Babraham Cambridge
Post Code: CB22 3FH
Country: United Kingdom
Membership Type: Corporate 21-50